Irinotecan chemotherapy associated with transient dysarthria and aphasia.
De Marco
S
S
Squilloni
E
E
Vigna
L
L
Bertagnolio
M F
MF
Sternberg
C N
CN
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001037:Aphasia / Q000139:chemically induced*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy; D004401:Dysarthria / Q000139:chemically induced*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007260:Infusion Pumps; D000077146:Irinotecan; D008297:Male
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin